US2005244852A1PendingUtilityA1
Secreted and transmembrane polypeptides and nucleic acids encoding the same
Est. expiryJun 25, 2018(expired)· nominal 20-yr term from priority
G01N 33/57585G01N 33/57555G01N 33/57535G01N 33/5759G01N 33/5758G01N 33/5752G01N 33/575C07K 14/82C07K 16/28C07K 14/4748C07K 14/47A61K 38/00C07K 2319/30G01N 2500/00A01K 2227/105C12Q 1/6883G01N 33/5308C12Q 1/6886A01K 2217/075G01N 33/5082C07K 14/705C12Q 1/6816C12Q 2600/136C12Q 2600/158
67
PatentIndex Score
0
Cited by
0
References
0
Claims
Abstract
The present invention is directed to novel polypeptides and to nucleic acid molecules encoding those polypeptides. Also provided herein are vectors and host cells comprising those nucleic acid sequences, chimeric polypeptide molecules comprising the polypeptides of the present invention fused to heterologous polypeptide sequences, antibodies which bind to the polypeptides of the present invention and to methods for producing the polypeptides of the present invention.
Claims
exact text as granted — not AI-modified1 . A diagnostic method, comprising determining, in a test biological sample obtained from a mammalian subject, the level of nucleic acid encoding a PRO1079 polypeptide of SEQ ID NO:2 relative to the level of said nucleic acid in a corresponding normal biological sample wherein increased level of said nucleic acid in the test biological sample is indicative that the test biological sample contains cancerous cells.
2 . The method of claim 1 wherein the test and normal biological samples are tissue samples.
3 . The method of claim 2 wherein the test tissue sample is from colon, lung, breast or rectal tissue.
4 . The method of claim 3 wherein the normal biological sample is from the same type of tissue as the test biological sample.
5 . The method of claim 4 wherein the normal biological sample is an epithelial tissue sample from a combination of tissues.
6 . The method of claim 5 wherein epithelial tissue sample includes epithelial cells from colon, lung, breast or rectal tissue.
7 . The method of claim 1 wherein the nucleic acid levels are determined by hybridization of nucleic acid obtained from the test and normal biological samples to one or more probes specific for the nucleic acid encoding PRO1079.
8 . The method of claim 6 wherein hybridization is performed under stringent conditions.
9 . The method of claim 8 wherein said stringent conditions use 50% formamide, 5×SSC, 50 mM sodium phosphate (pH 6.8), 0.1% sodium pyrophosphate, 5× Denhardt's solution, sonicated salmon sperm DNA (50 μg/ml), 0.1% SDS, and 10% dextran sulfate at 42° C., with washes at 42° C. in 0.2×SSC and 50% formamide at 55° C., followed by a wash comprising of 0.1×SSC containing EDTA at 55° C.
10 . The method of claim 7 wherein the nucleic acids obtained from the test and normal biological samples are cDNAs.
11 . The method of claim 10 wherein the nucleic acids obtained from the test and normal biological samples are placed on microarrays.
12 . A diagnostic method comprising determining the expression level of the PRO1079 polypeptide of SEQ ID NO:2 in test biological sample relative to a normal biological sample, wherein overexpression of said polypeptide in the test biological sample is indicative that the sample contains cancerous cells.
13 . The method of claim 12 wherein the test and normal biological samples are tissue samples.
14 . The method of claim 13 wherein the test tissue sample is from colon, lung, breast or rectal tissue.
15 . The method of claim 14 wherein overexpression is detected with an antibody that specifically binds to the PRO1079 polypeptide.
16 . The method of claim 15 wherein said antibody is a monoclonal antibody.
17 . The method of claim 16 wherein said antibody is a humanized antibody.
18 . The method of claim 17 wherein said antibody is an antibody fragment.
19 . The method of claim 18 wherein said antibody is labeled.Cited by (0)
No later patents cite this yet.
References (0)
No backward citations on record.